Market cap
$12.2m
End-of-day close multiplied by current shares on issue.
RUA · NZX
Rua Bioscience (RUA)
Healthcare / Medicinal cannabisCovered: HY22 - FY268 published briefings
Rua Bioscience is an NZX-listed healthcare / medicinal cannabis company. Its latest covered result is FY26, with HY22 - FY26 of source-backed result history on Annolyse.
Sections
Latest result
Latest metrics
FY26, released 28 August 2026
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $2.9m | ↑ +53.9% |
| Operating profit | -$3m | ↑ +7.6% |
| NPAT | -$3.4m | ↑ +2.9% |
| Operating cash flow | -$3m | ↓ -6.2% |
| OCF / Operating profit % | 97.1% | ↑ +12.6pp |
| Net debt | $1.2m | ↑ +144.5% |
| Net debt / Operating profit | n/m | — |
| ROE % | -79.9% | ↓ -9.3pp |
| PBT | -$3.4m | ↑ +2.9% |
| FCF pre-lease | -$3m | ↓ -6.2% |
Source: latest published briefing (FY26, released 28 August 2026). Change compares against the prior equivalent period: FY25, released 1 September 2025.
Valuation
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
Prices as at close, 4 September 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.01
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
2.87x
Market value compared with latest reported equity.
Income and investment-company measures
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
Chat
Ask about RUA
Ask follow-up questions about Rua Bioscience's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about RUA
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | FY2612 MONTHS28 August 2026 | HY266 MONTHS27 February 2026 | FY2512 MONTHS1 September 2025 | HY246 MONTHS29 February 2024 | FY2312 MONTHS29 August 2023 | HY236 MONTHS28 February 2023 | FY2212 MONTHS29 August 2022 | HY226 MONTHS25 February 2022 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9m | $1.3m | $1.9m | $0.02m | $6.5m | $0.25m | $0.65m | $360m | Chart |
| Revenue growth % | 93.5% | 92.2%Outside range high revenue growth. 92.2%; 3-period range -100% to 33.8%. Revenue growth: 92.2%, above normal range; 3-period mean -31.8%, range -100.0%-33.8%. | 490.0% | -100.0%Outside range low revenue growth. -100%; 3-period range -29.4% to 92.2%. Revenue growth: -100.0%, below normal range; 3-period mean 32.2%, range -29.4%-92.2%. | n/m | -29.4% | n/m | 33.8% | Chart
|
| Operating profit | -$3m | -$1.7m | -$3.3m | -$10.9m | -$6.1m | $0.63m | -$7.6m | -$3.9m | Chart |
| Operating profit margin % | -104.3% | -123.8% | -173.6% | n/m | -94.0% | n/m | n/m | -1.1% | Chart |
| PBT | -$3.4m | -$1.8m | -$3.5m | -$10.9m | -$6m | $0.7m | -$7.5m | -$3.5m | Chart |
| NPAT | -$3.4m | -$1.8m | -$3.5m | -$10.9m | -$6m | $0.7m | -$8.6m | -$2.5m | Chart |
| Operating cash flow | -$3m | -$1.5m | -$2.8m | -$2.1m | -$5.9m | -$3.7m | -$6.8m | -$3.7m | Chart |
| OCF / Operating profit % | 97.1% | 92.0% | 84.5% | 19.5% | 96.4% | -581.6% | 90.3% | 96.1% | Chart |
| FCF pre-lease | -$3m | — | -$2.8m | -$2.1m | — | — | — | -$4m | Chart |
| FCF post-lease | — | — | -$2.8m | — | — | — | — | — | — |
| DPS | — | — | — | 0.0c | — | — | — | — | — |
| ROE % | -79.9% | -59.3% | -70.6% | n/m | -29.6% | 2.7%Outside range high roe. 2.7%; 3-period range -114.5% to -9.3%. ROE: 2.7%, above normal range; 3-period mean -61.0%, range -114.5%--9.3%. | -32.6% | -9.3% | Chart
|
| Net debt | $1.2m | -$0.4m | $0.48m | -$0.8m | — | — | -$1.9m | -$2.3m | Chart |
| Net debt / Operating profit | n/m | 0.24x | n/m | 0.07x | — | — | 0.25x | 0.58x | Chart |
| Debtor days | 66 | 51 | 41 | — | 6 | — | — | — | Chart |
| Inventory days | 73 | 93 | 78 | n/m | 1 | 198 | 0 | 0 | Chart |
| Total assets | $7.2m | $8.7m | $6.8m | $10m | $21m | $29.1m | $33.6m | $28m | Chart |
Reference: annolyse.ai/companies/rua
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
- HY24 RUA HY: Outside range low revenue growth. -100%; 3-period range -29.4% to 92.2%. Revenue growth: -100.0%, below normal range; 3-period mean 32.2%, range -29.4%-92.2%.
- HY26 RUA HY: Outside range high revenue growth. 92.2%; 3-period range -100% to 33.8%. Revenue growth: 92.2%, above normal range; 3-period mean -31.8%, range -100.0%-33.8%.
EBITDA-equivalent
Company-specific earnings measure where disclosed.
Loading chart...
EBITDA margin
EBITDA-equivalent margin where revenue and earnings are source-backed.
Loading chart...
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
More financial metrics
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
FCF post-lease
Free cash flow after lease payments where available.
Loading chart...
ROE
Return on equity.
Loading chart...
- HY23 RUA HY: Outside range high roe. 2.7%; 3-period range -114.5% to -9.3%. ROE: 2.7%, above normal range; 3-period mean -61.0%, range -114.5%--9.3%.
Net debt
Borrowings less cash; negative values indicate net cash.
Loading chart...
DPS
Dividend per share declared for the period.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
Inventory days
Inventory days where the working-capital inputs are source-backed.
Loading chart...
Operating working-capital movement
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
Loading chart...
The setup & the reality
HY26 → FY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What HY26 said to watch
Previous analysisHY26Result releasedAnnolyse analysis published
From Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled
No quantified targets are disclosed. The release describes continued execution of a "capital-light strategy anchored in genetics and distribution" with product launches and German and UK market activity, but does not put numbers around H2.
The supplied seasonality shape is awkward: in FY25, HY25 represented only 36.5% of full-year revenue but 52.1% of full-year NPAT (because the second-half loss was smaller). Annualising HY26 revenue gives roughly NZ$2.7m, which would imply meaningful further H2 revenue growth, but the FY25 NPAT of -NZ$3.46m means the half-year loss run-rate needs to fall, not just hold, to materially improve the full-year outcome.
Open questions
Open questions from HY26
- How long does the current cash and debt structure fund the operating burn at the HY26 run-rate, and what are the borrowing terms, covenants and maturities?
- Why did inventories more than double, and how much of that build is committed to existing orders versus speculative stock for the German and UK channels?
- What does management see as the path and timeframe to operating breakeven, and what revenue level is required?
- Why has the asset base contracted so far below the historical range, and is further restructuring or impairment expected?
- Can the receivables improvement from 159 days to 51 days be sustained, or was it a one-off catch-up that flattered HY26 operating cash flow?
This briefing cannot assess product-level demand signals, channel sell-through, regulatory pipeline progress, or the specific terms attached to the new borrowings.
Latest result sources
Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
Current period
FY26 Preliminary Financial Results
FY26 / financial reportFY26 Preliminary Financial Results Announcement
FY26 / results announcementPrior comparable period
Rua Bioscience FY25 Annual Report
FY25 / financial reportRua Bioscience FY25 Annual Report Announcement
FY25 / results announcementInterim context
Half-Year Financial Results Announcement
HY26 / results announcementHalf-Year Financial Statements
HY26 / financial reportRelease context
ASM Presentation FY25
FY25 / commentaryASM Presentation FY25
HY26 / commentaryPeer context
Other covered Healthcare companies
These companies share a broad sector but may not be direct peers. Compare them only where the underlying measures are genuinely comparable.
Archive
Briefing archive
The full chronological archive contains every published result briefing.
FY26 · Released 28 August 2026
Revenue rose 93.5% while borrowings climbed 55.9%
Revenue reached $2.9m and cash rose to $0.534m, but operating cash outflow widened to $3.0m.
Read briefing
HY26 · Released 27 February 2026
Revenue grew to NZ$1.3m but losses persisted as borrowings quadrupled
A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.
Read briefing
FY25 · Released 1 September 2025
RUA revenue rose 490.6% but the business remains deeply cash-negative
Strong commercial momentum cut the loss before tax by 74.8%, yet cash fell to NZD 0.2m and operating outflows persist, making runway the central
Read briefing
HY24 · Released 29 February 2024
Goodwill impairment of $8.3m drives HY24 loss of $10.9m
Management writes off a prior acquisition that failed to deliver, leaving a $1.0m cash buffer and ongoing operating burn.
Read briefing
FY23 · Released 29 August 2023
Customer revenue $0.4m as cash burn $5.9m leaves $2.5m on hand
Headline revenue of $6.5m is dominated by fair value gains on contingent consideration; commercial revenue remains immaterial against ongoing burn.
Read briefing
HY23 · Released 28 February 2023
Reported $0.7m profit masks unchanged $3.7m cash burn against $1.7m balance
Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.
Read briefing
Get notified when RUA publishes
Get the next Rua Bioscience result briefing and five-year history updates by email.